Trial reportBMC anesthesiology2026
Superior autonomic regulation with ropivacaine over lidocaine in stellate ganglion block for chronic insomnia: a randomized controlled trial.
Trial report in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A multimodal sleep intervention improves sleep quality and architecture in chronic insomnia: a prospective exploratory study.Frontiers in medicine · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveThis study aimed to compare the efficacy of lidocaine versus ropivacaine in stellate ganglion block (SGB) for insomnia treatment, including sleep quality improvement, symptom relief, and autonomic nervous system regulation.
methodsSixty patients aged 18–75 years with insomnia were randomly divided into the ropivacaine group (Rop group) and lidocaine group (Lido group). Patients in Lido group received a 10-day SGB treatment using 0.8% lidocaine/3 ml. Patients in Rop group were treated with 0.2% ropivacaine/3 ml for SGB for 10 consecutive days. All patients received standard cognitive behavioral therapy. The results of Pittsburgh sleep quality index (PSQI), patient health Questionnaire-9 (PHQ-9), generalized anxiety Disord-7 (GAD-7) and heart rate variability (HRV) were observed and recorded before treatment (T1), the day after treatment completion (T2) and one month after treatment (T3).
resultsWithin-group analyses revealed that both groups showed significant improvements in the global PSQI score at T2 and T3, compared to T1 (both P < 0.05). Scores for PHQ-9 and GAD-7 also decreased significantly at T2 compared to T1 in both groups (P < 0.05). In terms of HRV, the Lido group exhibited significant within-group decreases in RMSSD and SDNN at T2 (P < 0.05), while the Rop group showed significant within-group decreases in the LF/HF ratio at T2 (P < 0.05). Crucially, between-group comparisons at T2 found no significant differences in PSQI, PHQ-9, or GAD-7 scores (P > 0.05). However, a significant between-group difference was observed in the LF/HF ratio, with the Rop group demonstrating a significantly lower value [0.7(0.5,1.2)] compared to the Lido group [1.2(0.9,2.9)] (P < 0.05).
conclusionSGB treatment with 0.2% ropivacaine and 0.8% lidocaine are equally effective for improving sleep and mood in insomnia. However, ropivacaine’s superior autonomic regulation makes it the preferred choice when mitigating sympathetic hyperactivity is a key therapeutic goal.
trial registrationThis study was registered in the Chinese Clinical Trial Registry (ChiCTR2500098835) on 2025/03/14.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.